MorphoSys, which owned a 20% stake following Lanthio's 2012 series A round, paid $22.5m for the remainder of the drug developer's shares.
Pharmaceutical firm MorphoSys has acquired one of its portfolio companies, Netherlands-based drug developer Lanthio Pharma, paying €20m ($22.5m) to acquire the 80% share it did not already own.
Lanthio develops lanthipeptides, therapeutics with a highly specified focus. Its lead compound, L2, is being developed to treat diabetic nephropathy and fibrotic diseases.
MorphoSys was one of the investors in Lanthio’s €4.8m series A round in 2012, which was co-led by BioGeneration Ventures and Inkef Capital, with participation from Hanzepoort.
Jens Holstein,…
